Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with PembrolizumabGlobeNewsWire • Wednesday
Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 02/14/24
Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with MyelofibrosisGlobeNewsWire • 12/21/23
Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 TrialGlobeNewsWire • 10/23/23
Galecto shares drop 65% as biotech halts development of lung-disease treatmentMarket Watch • 08/15/23
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary FibrosisGlobeNewsWire • 08/15/23
Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary FibrosisGlobeNewsWire • 05/23/23
Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022GlobeNewsWire • 03/09/23